Analyses of the differentiation potential of satellite cells from myoD -/-, mdx, and PMP22 C22 mice
- Marion M Schuierer†1Email author,
- Christopher J Mann†3,
- Heidi Bildsoe3,
- Clare Huxley2 and
- Simon M Hughes3
© Schuierer et al; licensee BioMed Central Ltd. 2005
Received: 10 November 2004
Accepted: 11 March 2005
Published: 11 March 2005
Sporadic and sometimes contradictory studies have indicated changes in satellite cell behaviour associated with the progressive nature of human Duchenne muscular dystrophy (DMD). Satellite cell proliferation and number are reportedly altered in DMD and the mdx mouse model. We recently found that satellite cells in MSVski transgenic mice, a muscle hypertrophy model showing progressive muscle degeneration, display a severe ageing-related differentiation defect in vitro. We tested the hypothesis that similar changes contribute to the gradual loss of muscle function with age in mdx and PMP22 mice, a model of human motor and sensory neuropathy type 1A (HMSN1A).
Single extensor digitorum longus muscle fibres were cultured from mdx and PMP22 mice and age- and genetic background-matched controls. Mice at several ages were compared with regard to the differentiation of satellite cells, assayed as the proportion of desmin-expressing cells that accumulated sarcomeric myosin heavy chain.
Satellite cells of 2 month, 6 month, and 12 month old mdx mice were capable of differentiating to a similar extent to age-matched wild type control animals in an in vitro proliferation/differentiation model. Strikingly, differentiation efficiency in individual 6 month and 12 month old mdx animals varies to a much higher extent than in age-matched controls, younger mdx animals, or PMP22 mice. In contrast, differentiation of myoblasts from all myoD null mice assayed was severely impaired in this assay system. The defect in satellite cell differentiation that occurs in some mdx animals arises from a delay in differentiation that is not overcome by IGF-1 treatment at any phase of cultivation.
Overall, a defect in satellite cell differentiation above that arising through normal ageing does not occur in mdx or PMP22 mouse models of human disease. Nonetheless, the impaired differentiation of satellite cells from some mdx animals suggests that additional factors, environmental or epigenetic, may lead to deteriorating muscle repair through poor differentiation of satellite cells in genetically predisposed individuals.
Like many muscle diseases, Duchenne muscular dystrophy (DMD) is characterised by a gradual loss of muscle function with age. Patients are initially ambulatory and have mild muscle pathology, despite ongoing degeneration and repair. In later stages of DMD, patients experience progressively more severe muscular changes, accompanied by loss of function, physical dependency, and ultimately, death .
DMD patients generally lack the cytoskeletal protein dystrophin, a member of the spectrin-like superfamily of actin binding proteins. Functional dystrophin is localised to the inner face of the sarcolemma and binds to cytoskeletal F-actin and transmembrane beta-dystroglycan as part of multiprotein complex that mediates signalling between the cytoskeleton and the extracellular matrix. The consequences of lack of dystrophin appear to be an enhanced susceptibility to fibre damage and possibly poor signalling between fibres and their environment. A milder form of dystrophin deficiency in humans is the Becker-Kiener type of muscular dystrophy (BMD). Here, dystrophin is not completely absent, but mutations lead to a quantitatively and/or qualitatively reduced gene product which does not accomplish its full function. The onset of BMD is generally later than DMD. In childhood, symptoms are usually very mild and muscle weakness becomes more evident only in the teens or twenties. BMD is non-lethal and patients often achieve normal life span, although the disease can progress in later life .
To date, it is not clear what controls disease progression in either DMD or BMD and no consensus has been reached in the literature. The progressive loss of muscle in DMD and other muscle disorders could be due to a sustained or increasing rate of degeneration above the rate of repair, or a progressive decline in the ability to regenerate the muscle. Some pathological changes appear to be similar to those observed in healthily ageing people, yet premature and exacerbated. A popular, yet challenged view is that in DMD, disease progression is attributable to accumulating deficiencies in the ability of satellite cells resident within the muscle to mediate regeneration and/or their own replacement . Satellite cell deficiencies could arise because of the excessive demands on repair mechanisms necessitated by the continuous degeneration of unstable muscle that does not express dystrophin. Indeed, symptoms of rapid early turnover of muscle fibre material and cells are apparent before birth in DMD patients , yet serious functional deficits arise only late in the first decade.
A commonly used model for studies of DMD is the mdx mouse. These animals, like human patients, show delayed onset of debilitating muscle degeneration. Although a transient burst of frank degeneration occurs in mdx mice during the period of muscle growth around the third postnatal week, degeneration leading to debility only occurs late in life, primarily in specific muscles, such as the diaphragm . In mdx mice, as in human DMD patients, disease is caused by the absence of functional dystrophin, owing to a nonsense mutation in exon 23. The relatively mild phenotype of mdx mice can, in part, be attributed to the compensatory function of the dystrophin-related protein utrophin, which is highly upregulated in regenerating muscle fibres in adult mdx mutants . Over time, enhanced muscle turnover and satellite cell numbers are also seen in mdx mice .
Other muscle diseases also show variable clinical progression. Human motor and sensory neuropathy type 1A (HMSN1A, also known as Charcot-Marie-Tooth disease type 1A, CMT1A) is a dominantly inherited demyelinating disorder of the peripheral nervous system. It is most frequently caused by over-expression of the PMP22 gene due to duplication of a 1.5-Mb region on chromosome 17, but it can also result from point mutations in the PMP22 gene [8–12]. The affected individuals typically have distal muscle weakness and atrophy often associated with mild to moderate sensory loss, depressed tendon reflexes, and high-arched feet. Individuals with HMSN1A experience slowly progressive weakness and atrophy of distal muscles in the feet and/or hands. Disease progression is variable for unknown reasons.
PMP22 C22 transgenic mice which were modified to harbour seven copies of the human PMP22 gene demonstrate developmental delays in myelination, decreased numbers of myelinated fibres, and abnormally thin myelin similar to HMSN1A . Being a neuropathy, PMP22 C22 mice can be used as reference animals that display a muscle phenotype without harbouring intrinsic muscle defects.
In a recent study, we found that satellite cells of MSVski transgenic mice display a differentiation defect compared to wildtype control animals and that this defect is exacerbated in ageing animals . Like mdx mice, hypertrophic MSVski transgenic mouse muscles have muscle degeneration that is initially efficiently repaired, but which eventually shows defective regeneration and frank muscle defects. In the present paper, we investigate the differentiation potential of satellite cells of single muscle fibres from the hypertrophic mdx and PMP22 mouse models and corresponding wildtype control animals in order to clarify whether ageing-related change in differentiation potential of satellite cells might influence disease progression.
mdx mice were obtained from a colony in the lab of T. Partridge (Imperial College, London, UK) and are similar to JAX C57BL/10ScSn-Dmd mdx /J. Control mice were obtained from JAX and were C57BL/10ScSn. MyoDm1 null mice were as reported . Mice were killed at ages of 6 to 8 weeks (referred to as 2 months), 22 to 25 weeks (referred to as 6 months), or 44 to 55 weeks (referred to as 12 months). Mice of the HMSN1A model PMP22 C22 and the corresponding age matched litter mate controls were received from the lab of C. Huxley at ages of 2 to 3 months (referred to as 2 months), 10 to 12 months (referred to as 11 months), and 15 months. Mice were kept in plastic cages with wire mesh lids in a 12:12-h light-dark cycle and fed ad libitum. Both sexes were used for each experimental time point to test for sex specific effects, although none were observed, and at least 4 mice of each genotype were used at each age. All animal experiments were carried out in accordance with the local ethics committee and UK Home Office approval.
Single fibre preparation
Single fibres from mouse EDL or soleus muscle were isolated and cultured in order to obtain satellite cells as described recently . Briefly, muscle tissue was dissected from mice of appropriate age and genotype in a manner that minimised injury, stretch, or other stress factors on the fibres. Connective tissue was removed by incubation in DMEM (Gibco, Paisley, UK) with 0.2% collagenase type I at 35°C for 1 h. Fibres were liberated by trituration in DMEM medium with Pasteur pipettes of different pore sizes. Fibres were fixed in 4% PFA, or placed in isolated wells of 8-well Permanox™ chamber slides (NalgeNunc International, Rochester, USA), coated with Matrigel (1 mg/ml in DMEM, BD Biosciences, Oxford, UK) for satellite cell cultivation and immunocytochemistry.
Satellite cell cultivation
Single fibres were allowed to adhere to the Matrigel matrix (3–5 mins), before adding 300 μl of plating medium (10% horse serum, HS (Gibco), 0.5% Chick Embryo Extract, CEE (Sera Laboratories International Ltd., Crawley, UK), in DMEM with 1% streptomycin/penicillin and 2% L-glutamine) and incubation in a humidified environment at 37°C and 5% CO2. After 3 days incubation to allow satellite cells to migrate off the fibre onto the Matrigel substrate, fibres were removed from the chambers and medium was replaced by proliferation medium (PM; 20% fetal calf serum, FCS, 10% HS, 2% CEE in DMEM). After further two days, PM was replaced by differentiation medium (DM ; 2% FCS in DMEM) and cells were allowed to differentiate for 2 or 5 days. Three days after plating and again after two days in proliferation medium, the total number of cells was analysed for each single fibre culture. To check for the influence of IGF-1 treatment on differentiation efficiency of satellite cells, PM, DM, or both were supplemented with 100 ng/ml of recombinant R3-IGF-1 (Sigma, Deisenhofen, Germany).
Slides were rinsed in PBS, fixed in cold methanol, blocked in 5% horse serum in PBS, and incubated with mAb against desmin (1/500, clone no. DE-U-10, IgG1; Sigma) and MyHC (1/10, A4.1025, IgG2a; ). Primary antibodies were successively detected with rat anti-mouse IgG1 (1:1,000; Serotec, Oxford, UK), FITC-conjugated goat anti-mouse IgG2a (1:100; Serotec, Oxford, UK), and Cy3-conjugated donkey anti-rat IgG (1:100; Jackson, USA). In the last antibody incubation, the DNA dye DAPI was added. Cells were washed, re-fixed in cold methanol and mounted with antifading agent. Cell differentiation was analysed by monitoring 10 randomly-selected fields of view equivalent to a total area of 5.45 mm2 of each chamber, representing approximately 15% of the area of each chamber. Differentiation efficiency (labelled 'Myoblast differentiation') was determined as the ratio of nuclei in myosin heavy chain positive (MyHC+) myocytes and/or myotubes divided by the total number of nuclei in desmin-expressing cells (desmin+ cells). Data presented reflect means and standard deviation of fibres from each of ≥ 4 animals unless otherwise stated. Cultures from ≥ 30 fibres were analysed in each case.
A sensitive assay for satellite cell differentiation
We checked that the myogenic cell yield and proliferation of satellite cells did not differ between myoD +/+, myoD +/-, and myoD -/- fibres (Fig. 1C). During the 2 days in PM around a 12- to 14-fold increase in cell numbers occurred, indicating an approximately 12 hour doubling time, independent of genotype.
The presence of non-myogenic cells and/or total cell density might affect myogenic differentiation efficiency. Therefore, we used desmin expression to discriminate between myogenic and non-myogenic cells. Differentiation efficiency in wells with different numbers of desmin positive (desmin+) or desmin negative (desmin-) cells for all cultures of myoD +/+, myoD +/, and myoD -/- fibres was compared (Fig. 1D). No effect of desmin- cells in the cultures was detected on the differentiation potential of the myogenic cells. On average, there were less than 11% non-myogenic cells in any cultures from mice of any genotype. Similarly, differentiation efficiency did not correlate with the density of either total cells or desmin+ cells; satellite cells are capable of differentiating (expressing MyHC) independently of cell fusion. Therefore, in this culture system, density of neither myogenic cells nor non-myogenic cells has a detectable influence on differentiation efficiency.
Differentiation potential of satellite cells from PMP22 transgenic mice
Differentiation potential of satellite cells of mdx mice
We have observed decline in differentiation capacity as satellite cells age in regenerating muscle . In the present study, satellite cells from control C57BL/10 mice yield high levels of differentiation at all ages examined with only a slight and not significant decrease with age (87% ± 3, 84% ± 5, and 82% ± 6 in fibres from 2, 6, and 12 month old mice, respectively; Fig. 3A). Similar experiments were performed for mdx animals of corresponding ages. Across all fibres from all mdx animals, no significant difference in differentiation in comparison to wildtype animals was observed. Mean differentiation efficiency was 80% (± 5) at 2 months old, 66% (± 15) at 6 months old, and 72% (± 20) at 12 months old mdx animals. However, as indicated by the high standard deviation, the variance in differentiation was extremely high in older animals.
We investigated the reason for the higher variance in differentiation of 6 and 12 month mdx cultures. Whereas numbers of cells per well and desmin+ or desmin- cell density showed no apparent contribution to variance, animal to animal differences were striking. Many individual mdx mice yielded satellite cells capable of differentiating as well as age-matched controls. However, some individual animals yielded particularly poorly differentiating cells (Fig. 3B). This variation could not be accounted for by day to day variation in culture conditions because age-matched mdx and wild type animals were always prepared in parallel. There was no indication of correlation with sex, health status, housing conditions, or season, although numbers of animals were too low to eliminate any of these variables with high confidence.
Differentiation defect of affected mdx satellite cells can be overcome by prolonged differentiation time
IGF-1 treatment does not influence the differentiation of satellite cells in vitro
As controls, we checked that the proportion of myogenic, desmin+ cells in the cultures was not altered significantly by IGF-1 treatment in relation to total cell number in either control or mdx. However, the fraction of non-myogenic cells was over three times greater in mdx (58% ± 6) than in controls (16% +/- 5), independent of IGF-1 treatment (Fig. 5B). As found in the experiments above, despite this difference in non-myogenic cell numbers, differentiation efficiency was comparable between mdx and controls (Fig. 5A).
Satellite cells are normally quiescent cells that reside under the basal lamina of muscle fibres. Under conditions of growth and repair, satellite cells become activated and begin a coordinated myogenic program: they initially proliferate and express a range of myogenic genes, including desmin, before aligning and fusing to form terminally differentiated multinucleate syncitia that organise and express the contractile apparatus, which includes the MyHC proteins. We have shown recently that, in MSVski transgenic mice, satellite cell differentiation in vitro was influenced by the age of the study animals and showed a progressive decline with age . This effect was much less obvious in wildtype control animals. Therefore, we concluded that a satellite cell differentiation defect developed in MSVski mice. We speculated that the defect might be caused by continual degeneration/repair apparent in hypertrophic MSVski mice and that the changes in satellite cells might underlie the worsening of the muscle pathological profile with age. The mdx mouse model of human DMD displays a hypertrophy phenotype in the skeletal musculature reminiscent of MSVski mice. Similarly, DMD patients initially show a mild phenotype that gradually progresses throughout the lifespan, manifesting as muscle loss and fibrosis which culminates in death from respiratory or cardiac failure. As the progression of DMD is not understood and because of similarities between DMD/mdx pathology and the MSVski animal phenotype we hypothesised that progressive defect in the differentiation potential of satellite cells might contribute to the pathologic mechanism of the debilitating human disease.
We find that satellite-derived cells from ageing mdx mice are, in general, capable of differentiating to the same degree as satellite-derived cells from control animals. We did not assess satellite-derived cells that remained physically juxtaposed to the explanted fibre because such cells could display different behaviour(s) due to variations in the fibre integrity or its surrounding matrix. We chose to measure differentiation as the fraction of desmin-expressing cells co-expressing MyHC rather than fusion for several reasons. Firstly, without using assays that detect syncitia , there is no way of clearly ascertaining whether two cells are truly fused or closely apposed. Secondly, mononucleate cells are capable of terminally differentiating and expressing MyHC; such cells would be missed if assessing fusion. Although we can not eliminate the possibility that the mdx condition leads to an alteration in the cells that express desmin, our study provides evidence against this view. First, yields of desmin+ cells are similar between mdx and control. Second, the proliferation rate of desmin+ cells appears similar between mdx and control. Third, and as discussed further below, although numbers of desmin- cells are increased in mdx cultures the increase is similar both before and after the differentiation phase suggesting that interconversion of desmin- and desmin+ cells is not a significant factor in our experiments. Overall, it is unlikely that a defect in differentiation of satellite-derived cells is a major contributor to disease progression in mdx mice.
Despite this lack of significant change in overall differentiation capacity, satellite-derived cells from some individual older mdx animals displayed lower differentiation efficiencies than those from other mdx animals of the same age. Age- and background genotype-matched control mice, young mdx mice, and mice with severe muscle weakness due to the PMP22 transgene did not show this variation. We were unable to correlate this effect to any factor analysed. All animals were held under similar conditions. We consciously used both genders and analysed data in combination of both sexes and separately. We conducted additional experiments using increased or decreased collagenase type I incubation times as well as a more severe collagenase type II digestion to determine if variations in satellite cell activation or yield, basal lamina digestion, or fibre damage could affect differentiation potential, but found no differences (data not shown). Similarly, we performed dilution cloning of satellite cells to assess the effects of proliferation rate on satellite cells and whereas we observed heterogeneity of proliferation rates amongst satellite cells grown from single cells, we again found no ultimate difference in differentiation efficiency (data not shown). For those reasons we can not explain the inter-animal variation of mdx results by differences in the experimental design or genetic background of the animal. We speculate that uncontrolled environmental effects or epigenetic factors affecting other genes in the mdx background explain the variation. It is striking that fibres yielding poorly-differentiating cells are numerous in affected individuals, but nevertheless, some fibres yield cells differentiating as well in controls. This emphasises that relatively heritable heterogeneity in myogenic cells must exist in mdx mice and demands elucidation. Moreover, we can not eliminate the possibility that the mdx individuals showing poor differentiation in our assay would have undergone a worse progression of disease in later life. Additionally, we cannot exclude the possibility that very subtle differences in differentiation behaviour were not detected in our assay system as we have utilized matrigel, a matrix in which growth factors are abundant. Thus, small variations might have been masked that only would be detectable at the application of collagen or gelatine matrices.
As shown by others  and in this report, non-myogenic cells, probably fibroblasts, can be obtained from single fibre cultures and are more abundant in mdx samples compared with C57BL/10 controls. These cells probably reside on the fibre surface and migrate away from the fibre onto the substrate as do satellite-derived cells. In vivo, these cells may mediate the fibrotic response to fibre degeneration and could potentially secrete factors such as TGF-β that have been shown to interfere with satellite cell differentiation . We analysed the proportion of non-myogenic cells in the cultures and whether they influenced the efficiency of differentiation of myogenic cells. We were unable to find a correlation between the contamination of the satellite cell culture with desmin- non-myogenic cells and the differentiation efficiency of the myogenic cells in the same culture well. This confirms what we have observed in wild type, MSVski, PMP22, and myoD null situations . There was also no difference in desmin- cell levels between mice showing poor or normal differentiation. Thus, at least in mdx animals up to one year of age, no correlation of fibrosis with poor myoblast differentiation is apparent.
Differentiation is delayed, not inhibited in some mdx mice
We found that satellite-derived cells from mdx mice showing poor differentiation after two days differentiation, recovered and differentiated as well as controls after three further days in differentiation conditions. No morphological differences in the nature of the differentiated cells were detected at this stage. Thus, the reduction in differentiation observed in some mdx animals is most simply explained as a reduced rate of differentiation. If such a decrease in differentiation rate occurs in vivo, it could have serious consequences for muscle repair, which may require rapid satellite cell mobilisation and can occur within a few days .
IGF-1 treatment has been shown to enhance the efficiency of differentiation of satellite-derived myoblasts and this has been suggested to mediate an autocrine loop triggered by myogenin expression . However, IGF-1 treatment of poorly-differentiating mdx satellite-derived cells did not enhance their differentiation rate. Moreover, although it has been reported that IGF-treatment of wildtype myogenic cells leads to enhanced proliferation [24, 25], in our experimental conditions using recombinant R3 IGF-I we were not able to confirm those findings.
Functional impairment in HMSN1A model mice is not accompanied by satellite cell changes
A rodent model for the progressive human neuropathy HMSN1A is the PMP22 C22 transgenic mouse that harbours seven copies of the human PMP22 gene in its genome. These animals manifest symptoms similar to human HMSN1A patients including demyelination of Schwann cells and, with later age, progressive skeletal muscle weakness caused by poor innervation . Examination of postural soleus muscle from such mice revealed a heterogeneous progression of muscle pathology. Some animals showed severe signs of atrophic fibres and changes in fibre type proportion, probably caused by altered electrical activity consequent to slowed nerve conduction. Other individuals, which also showed poor movement, had relatively healthy muscle histology. A cohort of affected PMP22 C22 mice with altered gait were analysed by single fibre culture and revealed no changes in number, proliferation, or differentiation of desmin+ cells compared to age- and genetic background-matched controls. Thus, the HMSN1A model mice show a strong phenotype which seems to involve muscle fibre atrophy after demyelination of its innervating motorneuron followed by satellite cell recruitment in the regrowth phase after myelination is restored. However, these processes have no observable effect on mononucleate cells in single fibre cultures.
Differentiation defect in satellite cells lacking myoD
There has been controversy surrounding the role of the myogenic transcription factor MyoD in satellite cell differentiation. Early reports suggested the myoD null muscle regenerated poorly and that myoblasts from young myoD null mice differentiated poorly in vitro [17, 26]. However, a recent study showed the myoD null satellite cells can differentiate efficiently under some circumstances . In our single EDL muscle fibre cultures, satellite-derived myoblasts from wild type or heterozygous myoD +/- mice differentiate efficiently. In contrast, few desmin-expressing satellite-derived cells from myoD deficient mice were able express MyHC within two days. Given the rapid repair of entire muscles within several days of toxin-induced injury , the differentiation delay in myoD null would have severe consequences in wild populations if a similar delay occurred in any in vivo setting.
An issue not addressed directly by our study is the relationship of the assayed population of desmin-expressing cells from wild type to that from myoD null animals. For example, lack of myoD might cause a change in the numbers of cells expressing desmin. We think this unlikely because the yield of desmin+ cells, and the ratio of desmin+ to desmin- cells, were unaltered in our single fibre cultures, irrespective of myoD genotype. Whatever the case, our experiment shows that lack of myoD leads to substantial reduction in the capacity of muscle fibre-associated migratory proliferative cells to undergo terminal differentiation into myotubes.
As there appears to be no distinct differentiation defect in the satellite cells of mdx mice, at least by our assay, the cause of progressive muscle loss in the diseased state remains unclear. The differentiation potential of satellite cells has generated contradictory results in several early studies, where differentiation was measured as myoblast fusion in primary cultures (reviewed in [28, 29]). One study concluded no differentiation defect , whereas Jasmin and colleagues found a reduced differentiative capacity in myoblasts derived from DMD patients . A very recent publication by Schaefer et al. also revealed heterogeneity in the number of satellite cells between individual mdx and C57 animals. The authors observed that this heterogeneity did not correlate with age, gender, or degree of degeneration, but possibly reflected additional genetic factors that influence the maintenance of the satellite cell pool .
Altered myoblast number appears not to explain disease progression. Some studies find an increase in the number of satellite cells associated with DMD/mdx muscle fibres ([32–35] and our unpublished observations), although others observe little change . Thus loss of available cells for repair is unlikely to cause disease progression. Despite reports of increased cell death in DMD/mdx myoblasts [36–38], we found no evidence of differential apoptosis between control and mdx. It has also been suggested that decreased proliferative potential and early senescence of satellite cells is the primary cause of disease progression [3, 39]. One group measured this limitation as an accelerated age-related shortening of satellite cell telomere length , a result contradicted by another study using a similar assay . We observed no change in proliferative capacity of mdx satellite-derived cells. These findings suggest that the proliferative potential of satellite cells or their ability to self renew is not compromised; the number of satellite cells remains higher than controls throughout the lifespan of the animals (; our observations).
In summary, our study is the first to provide data on the differentiation efficiency of satellite cells in older mdx and PMP22 C22 mice. We found that, generally, the age of the individual animal had little impact on the differentiation of satellite cells. The pathological processes in muscle of mice with mdx or PMP22 C22 genotype are not necessarily accompanied by defects in satellite cell differentiation. However, in some mdx individuals, satellite cell differentiation is impaired after the age of two months, in a manner akin to that we observed in MSVski hypertrophic muscle pathology . It seems clear that there is heterogeneity in the pathology of muscle in various animal models of human disease, probably due to epigenetic/environmental contributions. It remains to be further investigated what causes cases of poor differentiation and whether this impaired differentiation of satellite cells enhances deterioration of the physical condition of the individual.
List of abbreviations
Becker type muscular dystrophy
Chick embryo extract
Charcot-Marie-Tooth disease type 1A
Duchenne muscular dystrophy
Dulbecco's Modified Eagle's Medium
Extensor digitorum longus
fetal calf serum
Hereditary Motor and Sensory Neuropathy type1A
insulin-like growth factor 1
Master seed virus
Myosin heavy chain
phosphate buffered saline
- PMP 22:
Peripheral myelin protein 22
The work was funded by Muscular Dystrophy Campaign and MRC grants to SMH. Thanks to Alison Maggs for PMP22 analyses.
- Hoffmann EP: Dystrophinopathies. Edited by: Karpati GHJDGRC. Cambridge University Press; 2001:385-432.
- Nigro V, Nigro G, Esposito MG, Comi LI, Molinari AM, Puca GA, Politano L: Novel small mutations along the DMD/BMD gene associated with different phenotypes. Hum Mol Genet. 1994, 3: 1907-1908.View ArticlePubMedGoogle Scholar
- Webster C, Blau HM: Accelerated age-related decline in replicative life-span of Duchenne muscular dystrophy myoblasts: implications for cell and gene therapy. Somat Cell Mol Genet. 1990, 16: 557-565. 10.1007/BF01233096.View ArticlePubMedGoogle Scholar
- Blau HM, Webster C, Pavlath GK: Defective myoblasts identified in Duchenne muscular dystrophy. Proc Natl Acad Sci U S A. 1983, 80: 4856-4860.View ArticlePubMedPubMed CentralGoogle Scholar
- Pastoret C, Sebille A: Age-related differences in regeneration of dystrophic (mdx) and normal muscle in the mouse. Muscle Nerve. 1995, 18: 1147-1154. 10.1002/mus.880181011.View ArticlePubMedGoogle Scholar
- Weir AP, Morgan JE, Davies KE: A-utrophin up-regulation in mdx skeletal muscle is independent of regeneration. Neuromuscul Disord. 2004, 14: 19-23. 10.1016/j.nmd.2003.09.004.View ArticlePubMedGoogle Scholar
- Reimann J, Irintchev A, Wernig A: Regenerative capacity and the number of satellite cells in soleus muscles of normal and mdx mice. Neuromuscul Disord. 2000, 10: 276-282. 10.1016/S0960-8966(99)00118-2.View ArticlePubMedGoogle Scholar
- Chance PF, Reilly M: Inherited neuropathies. Curr Opin Neurol. 1994, 7: 372-380.View ArticlePubMedGoogle Scholar
- Lupski JR, Garcia CA: Molecular genetics and neuropathology of Charcot-Marie-Tooth disease type 1A. Brain Pathol. 1992, 2: 337-349.View ArticlePubMedGoogle Scholar
- Nelis E, Warner LE, Vriendt ED, Chance PF, Lupski JR, Van Broeckhoven C: Comparison of single-strand conformation polymorphism and heteroduplex analysis for detection of mutations in Charcot-Marie-Tooth type 1 disease and related peripheral neuropathies. Eur J Hum Genet. 1996, 4: 329-333.PubMedGoogle Scholar
- Roa BB, Garcia CA, Suter U, Kulpa DA, Wise CA, Mueller J, Welcher AA, Snipes GJ, Shooter EM, Patel PI, .: Charcot-Marie-Tooth disease type 1A. Association with a spontaneous point mutation in the PMP22 gene. N Engl J Med. 1993, 329: 96-101. 10.1056/NEJM199307083290205.View ArticlePubMedGoogle Scholar
- Robaglia-Schlupp A, Pizant J, Norreel JC, Passage E, Saberan-Djoneidi D, Ansaldi JL, Vinay L, Figarella-Branger D, Levy N, Clarac F, Cau P, Pellissier JF, Fontes M: PMP22 overexpression causes dysmyelination in mice. Brain. 2002, 125: 2213-2221. 10.1093/brain/awf230.View ArticlePubMedGoogle Scholar
- Robertson AM, Huxley C, King RH, Thomas PK: Development of early postnatal peripheral nerve abnormalities in Trembler-J and PMP22 transgenic mice. J Anat. 1999, 195: 331-339. 10.1046/j.1469-7580.1999.19530331.x.View ArticlePubMedPubMed CentralGoogle Scholar
- Charge SB, Brack AS, Hughes SM: Aging-related satellite cell differentiation defect occurs prematurely after Ski-induced muscle hypertrophy. Am J Physiol Cell Physiol. 2002, 283: C1228-C1241.View ArticlePubMedGoogle Scholar
- Rudnicki MA, Braun T, Hinuma S, Jaenisch R: Inactivation of MyoD in mice leads to up-regulation of the myogenic HLH gene Myf-5 and results in apparently normal muscle development. Cell. 1992, 71: 383-390. 10.1016/0092-8674(92)90508-A.View ArticlePubMedGoogle Scholar
- Dan-Goor M, Silberstein L, Kessel M, Muhlrad A: Localization of epitopes and functional effects of two novel monoclonal antibodies against skeletal muscle myosin. J Muscle Res Cell Motil. 1990, 11: 216-226.View ArticlePubMedGoogle Scholar
- Cornelison DD, Olwin BB, Rudnicki MA, Wold BJ: MyoD(-/-) satellite cells in single-fiber culture are differentiation defective and MRF4 deficient. Dev Biol. 2000, 224: 122-137. 10.1006/dbio.2000.9682.View ArticlePubMedGoogle Scholar
- Allen RE, Boxhorn LK: Regulation of skeletal muscle satellite cell proliferation and differentiation by transforming growth factor-beta, insulin-like growth factor I, and fibroblast growth factor. J Cell Physiol. 1989, 138: 311-315. 10.1002/jcp.1041380213.View ArticlePubMedGoogle Scholar
- Mohler WA, Simske JS, Williams-Masson EM, Hardin JD, White JG: Dynamics and ultrastructure of developmental cell fusions in the Caenorhabditis elegans hypodermis. Curr Biol. 1998, 8: 1087-1090. 10.1016/S0960-9822(98)70447-6.View ArticlePubMedGoogle Scholar
- McGeachie JK, Grounds MD, Partridge TA, Morgan JE: Age-related changes in replication of myogenic cells in mdx mice: quantitative autoradiographic studies. J Neurol Sci. 1993, 119: 169-179. 10.1016/0022-510X(93)90130-Q.View ArticlePubMedGoogle Scholar
- Melone MA, Peluso G, Petillo O, Galderisi U, Cotrufo R: Defective growth in vitro of Duchenne Muscular Dystrophy myoblasts: the molecular and biochemical basis. J Cell Biochem. 1999, 76: 118-132. 10.1002/(SICI)1097-4644(20000101)76:1<118::AID-JCB12>3.0.CO;2-F.View ArticlePubMedGoogle Scholar
- Irintchev A, Salvini TF, Faissner A, Wernig A: Differential expression of tenascin after denervation, damage or paralysis of mouse soleus muscle. J Neurocytol. 1993, 22: 955-965. 10.1007/BF01218353.View ArticlePubMedGoogle Scholar
- Stewart CE, James PL, Fant ME, Rotwein P: Overexpression of insulin-like growth factor-II induces accelerated myoblast differentiation. J Cell Physiol. 1996, 169: 23-32. 10.1002/(SICI)1097-4652(199610)169:1<23::AID-JCP3>3.0.CO;2-G.View ArticlePubMedGoogle Scholar
- Chakravarthy MV, Booth FW, Spangenburg EE: The molecular responses of skeletal muscle satellite cells to continuous expression of IGF-1: implications for the rescue of induced muscular atrophy in aged rats. Int J Sport Nutr Exerc Metab. 2001, 11 Suppl:S44-8.: S44-S48.Google Scholar
- Haugk KL, Wilson HM, Swisshelm K, Quinn LS: Insulin-like growth factor (IGF)-binding protein-related protein-1: an autocrine/paracrine factor that inhibits skeletal myoblast differentiation but permits proliferation in response to IGF. Endocrinology. 2000, 141: 100-110. 10.1210/en.141.1.100.PubMedGoogle Scholar
- Kablar B, Krastel K, Tajbakhsh S, Rudnicki MA: Myf5 and MyoD activation define independent myogenic compartments during embryonic development. Dev Biol. 2003, 258: 307-318. 10.1016/S0012-1606(03)00139-8.View ArticlePubMedGoogle Scholar
- Yablonka-Reuveni Z, Rudnicki MA, Rivera AJ, Primig M, Anderson JE, Natanson P: The transition from proliferation to differentiation is delayed in satellite cells from mice lacking MyoD. Dev Biol. 1999, 210: 440-455. 10.1006/dbio.1999.9284.View ArticlePubMedGoogle Scholar
- Witkowski JA: Tissue culture studies of muscle disorders: Part 1. Techniques, cell growth, morphology, cell surface. Muscle Nerve. 1986, 9: 191-207. 10.1002/mus.880090302.View ArticlePubMedGoogle Scholar
- Witkowski JA: Tissue culture studies of muscle disorders: Part 2. Biochemical studies, nerve-muscle culture, metabolic myopathies, and animal models. Muscle Nerve. 1986, 9: 283-298. 10.1002/mus.880090402.View ArticlePubMedGoogle Scholar
- Jasmin G, Tautu C, Vanasse M, Brochu P, Simoneau R: Impaired muscle differentiation in explant cultures of Duchenne muscular dystrophy. Lab Invest. 1984, 50: 197-207.PubMedGoogle Scholar
- Schafer R, Zweyer M, Knauf U, Mundegar RR, Wernig A: The ontogeny of soleus muscles in mdx and wild type mice. Neuromuscul Disord. 2005, 15: 57-64. 10.1016/j.nmd.2004.09.011.View ArticlePubMedGoogle Scholar
- Bockhold KJ, Rosenblatt JD, Partridge TA: Aging normal and dystrophic mouse muscle: analysis of myogenicity in cultures of living single fibers. Muscle Nerve. 1998, 21: 173-183. 10.1002/(SICI)1097-4598(199802)21:2<173::AID-MUS4>3.0.CO;2-8.View ArticlePubMedGoogle Scholar
- Ishimoto S, Goto I, Ohta M, Kuroiwa Y: A quantitative study of the muscle satellite cells in various neuromuscular disorders. J Neurol Sci. 1983, 62: 303-314. 10.1016/0022-510X(83)90207-1.View ArticlePubMedGoogle Scholar
- Maier F, Bornemann A: Comparison of the muscle fiber diameter and satellite cell frequency in human muscle biopsies. Muscle Nerve. 1999, 22: 578-583. 10.1002/(SICI)1097-4598(199905)22:5<578::AID-MUS5>3.0.CO;2-T.View ArticlePubMedGoogle Scholar
- Wakayama Y, Schotland DL, Bonilla E, Orecchio E: Quantitative ultrastructural study of muscle satellite cells in Duchenne dystrophy. Neurology. 1979, 29: 401-407.View ArticlePubMedGoogle Scholar
- Sandri M, Minetti C, Pedemonte M, Carraro U: Apoptotic myonuclei in human Duchenne muscular dystrophy. Lab Invest. 1998, 78: 1005-1016.PubMedGoogle Scholar
- Tews DS, Goebel HH: DNA-fragmentation and expression of apoptosis-related proteins in muscular dystrophies. Neuropathol Appl Neurobiol. 1997, 23: 331-338. 10.1046/j.1365-2990.1997.5998059.x.View ArticlePubMedGoogle Scholar
- J S, G F, PN SCHOFIELD: Programmed cell-death in dystrophic (mdx) muscle is inhibited by IGF-II. CELL DEATH DIFFER. 1995, 2: 234-251.Google Scholar
- Blau HM, Webster C, Chiu CP, Guttman S, Chandler F: Differentiation properties of pure populations of human dystrophic muscle cells. Exp Cell Res. 1983, 144: 495-503. 10.1016/0014-4827(83)90431-7.View ArticlePubMedGoogle Scholar
- Decary S, Hamida CB, Mouly V, Barbet JP, Hentati F, Butler-Browne GS: Shorter telomeres in dystrophic muscle consistent with extensive regeneration in young children. Neuromuscul Disord. 2000, 10: 113-120. 10.1016/S0960-8966(99)00093-0.View ArticlePubMedGoogle Scholar
- Oexle K, Zwirner A, Freudenberg K, Kohlschutter A, Speer A: Examination of telomere lengths in muscle tissue casts doubt on replicative aging as cause of progression in Duchenne muscular dystrophy. Pediatr Res. 1997, 42: 226-231.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2474/6/15/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.